Business
Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced a year-end recap of its pivotal 2025 achievements. The company delivered remarkable financial performance, operational expansion, and strategic milestones, positioning itself for sustained growth and an anticipated Nasdaq uplisting."2025 has been a defining year of execution and momentum for Adia...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced a year-end recap of its pivotal 2025 achievements. The company delivered remarkable financial performance, operational expansion, and strategic milestones, positioning itself for sustained growth and an anticipated Nasdaq uplisting.","length":432,"tagName":"p"},{"type":"text","content":""2025 has been a defining year of execution and momentum for Adia Nutrition," said Larry Powalisz, CEO of Adia Nutrition Inc. "From triple-digit revenue surges to sharpening our focus on high-margin regenerative therapies, we've built a strong foundation for scalable success while advancing toward greater visibility and accessibility for investors through our Nasdaq aspirations."","length":406,"tagName":"p"},{"type":"text","content":"Key 2025 Highlights:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"OTCQB Uplisting and SEC Rule 15c2-11 Compliance — Successfully uplisted from OTC Pink to the OTCQB Venture Market in a record-breaking six weeks, alongside completion of SEC Rule 15c2-11 compliance, enhancing transparency, liquidity, and investor confidence.","length":258,"tagName":"p"}]},{"val":[{"type":"text","content":"Explosive Revenue Growth — Preliminary and confirmed Q3 results showed revenue surging over 200% quarter-over-quarter, with earlier reports indicating more than 100% growth and profit margins exceeding 20%. This performance reflects strong demand for Adia Med's regenerative treatments and Adia Labs' innovative products.","length":339,"tagName":"p"}]},{"val":[{"type":"text","content":"Sales Infrastructure Expansion — The company tripled its sales force and established four dedicated regional divisions (East Coast, West Coast, Central U.S., and International), accelerating distribution of flagship therapies like AdiaVita and AdiaLink.","length":263,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic Partnerships and Market Access — Adia became a preferred vendor for the PI Doctors Elite Community, providing access to over 4,000 personal injury physicians nationwide and tapping into the $50 billion personal injury care market.","le...